Clinical Trial: High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926217) titled 'High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy' on Nov. 03.

Brief Summary: This randomized trial will compare the immune responses to high-dose and standard-dose influenza vaccines in 60 adults with blood cancers (hematologic malignancies) who have received B-cell-depleting therapy. Participants will be assigned by chance, in a 1:1 ratio, to receive one of the two vaccines. Antibody and T-cell responses will be measured before and after vaccination. Participants and their treating clinicians will know which vaccine is given. Laboratory staff who measure a...